Corbus Pharmaceuticals Holdings, Inc. current report, 18 May 2022

Full document

Corbus Pharmaceuticals Holdings, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Corbus Pharmaceuticals Holdings, Inc. (CRBP) on May 18, 2022. The filing details the results of the Company's Annual Meeting of Stockholders held on the same date.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.

Material Changes and Voting Results

The Annual Meeting addressed three primary matters:

  • Election of Directors: Six nominees were elected to one-year terms. Significant broker non-votes (41,974,844) were recorded for all director elections.
    • Yuval Cohen, Ph.D.: 28,846,457 For; 3,434,290 Withheld.
    • Alan Holmer: 28,595,858 For; 3,684,889 Withheld.
    • Avery W. Catlin: 29,131,782 For; 3,148,965 Withheld.
    • Rachelle Jacques: 28,973,906 For; 3,306,841 Withheld.
    • John Jenkins: 27,462,059 For; 4,818,688 Withheld.
    • Peter Salzmann: 27,638,662 For; 4,642,085 Withheld.
  • Ratification of Auditors: The appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, was approved.
    • Votes For: 66,313,203
    • Votes Against: 1,061,423
    • Abstentions: 6,880,965
  • Executive Compensation (Say-on-Pay): The advisory proposal regarding executive compensation was approved.
    • Votes For: 28,111,125
    • Votes Against: 3,791,024
    • Abstentions: 378,598
    • Broker Non-Votes: 41,974,844

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management commentary on business outlook, specific risks, contingencies, or unusual items.

Key Facts for Investor Verification

  • Verify the total number of shares entitled to vote to contextualize the high volume of broker non-votes (approx. 42 million) in the director and compensation votes.
  • Confirm the tenure and background of the newly elected directors, particularly given the varying levels of "Withheld" votes among nominees.
  • Review the definitive proxy statement referenced in the filing for detailed executive compensation data.
  • Check subsequent filings for the Company's financial performance, as this 8-K contains no financial data.